Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
Ha-Young Park, In-Jae Oh, Bo Gun Kho, Tae-Ok Kim, Hong-Joon Shin, Cheol Kyu Park, Yong-Soo Kwon, Yu-Il Kim, Sung-Chul Lim, Young-Chul Kim, Yoo-Duk Choi
Tuberc Respir Dis. 2019;82(3):227-233.   Published online 2019 Feb 28     DOI: https://doi.org/10.4046/trd.2018.0070
Citations to this article as recorded by Crossref logo
Recent advances in diagnostic technologies in lung cancer
Hye Jung Park, Sang Hoon Lee, Yoon Soo Chang
The Korean Journal of Internal Medicine.2020; 35(2): 257.     CrossRef
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Da Hyun Kang, Cheol-Kyu Park, Chaeuk Chung, In-Jae Oh, Young-Chul Kim, Dongil Park, Jinhyun Kim, Gye Cheol Kwon, Insun Kwon, Pureum Sun, Eui-Cheol Shin, Jeong Eun Lee
Immune Network.2020;[Epub]     CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Lee, Kim, Sung, Lee, Han, Kim, Choi
International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef